SUMMIT DETAILS

Since the inaugural meeting held at the Royal Society in London 2013, The E-Cigarette Summit has been at the forefront of expanding and forwarding the scientific and public health discussions around e-cigarettes and broader harm reduction debates.  Now, eight years on the Summit welcomes scientists, regulators, public health professionals and policy makers from around the world who are looking to establish their own regulatory framework in the face of new nicotine products.

There’s no doubt that the global dialogue surrounding Tobacco Harm Reduction (THR) and specifically e-cigarettes has become increasingly fraught.  The EVALI crisis and rising youth use reported during 2019, intensified what was already an emotional and divisive debate and the impact on global Governmental actions and public confidence in vaping has been significant. During this time of global uncertainty around the benefits and risks of e-cigarettes a sober analysis of THR in all of its ramifications has perhaps never been more necessary.  2021 will be another Watershed year for electronic cigarettes, the UK’s departure from the European Union, the upcoming European Tobacco Product Directive’s review and the imminent announcements and implementation of the PMTA  will all have material impacts on the regulatory and policy environment for e-cigarettes and reduced risk products.

2021 TOPICS

Smoking is the biggest single cause of preventable death in the developed world with almost 1 billion users worldwide. Despite decades of tobacco control efforts and public health education on the harms of smoking, the decline in smoking rates has been frustratingly slow. The E-Cigarette Summit provides a much-needed neutral platform to explore the available peer reviewed evidence and debate the issues that are dividing scientists, health professionals and policy makers alike. The E-Cigarette Summit has a single aim of facilitating respectful dialogue and thoughtful analysis of the latest research and to discuss how the evidence should be interpreted and communicated to deliver the most effective health strategies to reduce smoking related death and disease.

DAY ONE: 7 DECEMBER 2021

DAY TWO: 8 DECEMBER 2021

Session 1: Science & Evidence

  • OPENING KEYNOTE  What will success look like?
  • Depolarizing E-Cigarette Research: The need for epistemic humility
  • Do e-cigarettes help people quit smoking? A plea to focus on the evidence
  • The need to unbias the application of competing interest principles in e-cigarette research
  • Could e-cigarettes contribute to harm reduction for children as well as adults?

Session 2: Tobacco Harm Reduction & Tobacco Control

  • Is there a place for low-risk nicotine ‘alternatives’ on the market when smoking is about to disappear? 
  • The tobacco control climate in Germany
  • Reconsidering the meaning of tobacco harm reduction
  • Australia doubles down on its e-cigarette sales ban
  • The new tobacco wars

Session 3: Tobacco control, Regulation & Enforcement

  • The MHRA Regulatory Update
  • Trading standards and enforcement in the UK
  • Balancing regulation to achieve intended consequences
  • UK Policy and regulation

Session 4: Tobacco Harm Reduction & Public Health Policy

  • Vaping in the UK – Steady as she goes
  • Title TBC
  • The 2021 review of NICE’s tobacco guidelines
  • Combustible Tobacco Age-of-Sale Laws: An Opportunity?
  • The potential role of the cigarette industry in the future of the e-cigarette market

Session 5: Tobacco Harm Reduction, Research & Policy

  • E-cigarette research: Misinterpretation and selective use of evidence guiding regulatory decisions
  • Absolute and relative risks of electronic cigarettes
  • Nicotine and pregnant smokers
  • The impact of the COVID-19 pandemic on e-cigarette and tobacco use in the UK
  • Depression causes vaping!

Session 6: Nicotine & Public Health

  • Shifting the Paradigm: Tobacco Control and Tobacco Harm Reduction are Scientifically Complementary Approaches
  • Parents: The Untapped Resource for Balancing Cessation and Prevention Needs
  • Meeting people where they are and not where we think they should be
  • How tobacco harm reduction pragmatism has opened up opportunities for smokers facing severe disadvantage 
  • CLOSING KEYNOTE:  Covid-19 and tobacco harm reduction: are there lessons from the pandemic for the way ahead?

Paul Lincoln OBE

Chair - Tobacco: preventing uptake, promoting quitting and treating tobacco dependence

(NICE) National Institute of Clinical and Health Excellence -

Deborah Arnott

Chief Executive

Action on Smoking and Health

Hazel Cheeseman

Deputy Chief Executive & Policy Director

ASH (Action on Smoking & Health)

Dr Colin Mendelsohn MB BS (Hons)

General practitioner, Founding Chairman

Australian Tobacco Harm Reduction Association

Louise Ross

Interim Chair and Mental Health Lead for the New Nicotine Alliance

Business Development Manager - Smoke Free - Quit Smoking Now

Prof Daniel Kotz

Professor in addiction research and clinical epidemiology, Institute of General Practice

Centre for Health and Society, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Germany

Prof Linda Bauld, OBE

Bruce and John Usher Chair in Public Health in the Usher Institute

College of Medicine, University of Edinburgh

Clive Bates

Director

Counterfactual Consulting Ltd

Prof Lion Shahab

Professor of Health Psychology

Department of Behavioural Science and Health, University College London

Dr Michael Pesko

Health Economist & Associate Professor

Department of Economics, Andrew Young School of Policy Studies, Georgia State University

Tim Phillips

Managing Director

ECigIntelligence/TobaccoIntelligence

Andrea Crossfield MBE

Independent Public Health Consultant and Population Health Policy Specialist

Greater Manchester Health and Social Care Partnership

Prof Alan Boobis, OBE

Emeritus Professor of Toxicology & Chair - UK Committee on Toxicity

Imperial College London

Marcus Saxton

Chairman

Independent British Vape Trade Association (IBVTA)

Prof Ann McNeill

Professor of Tobacco Addiction

Institute of Psychiatry, Psychology & Neuroscience,, Kings College London

Prof David Levy

Professor of Oncology

Lombardl Comprehensive Cancer Center, Georgetown University

Kate Pike

Co-ordinator - Trading Standards North West

Member of the Department of Health and Social Care National Tobacco Focus Group

Craig Copland

E-Cigarette Unit Manager - Vigilance and Risk Management of Medicines

MHRA - The Medicines and Healthcare products Regulatory Agency

Dr Debbie Robson RMN, PhD

Senior Lecturer in Tobacco Harm Reduction

National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London

Marc Gunther

Reporter/Journalist

Nonprofit Chronicles/Freelance

Dr Karl E. Lund

Senior Researcher

Norwegian Institute of Public Health

Rosanna O’Connor

Director, Addictions & Inclusion

Office for Health Improvement & Disparities, Department of Health and Social Care

Martin Dockrell

Tobacco Control Programme Lead

Office of Health Improvement & Disparities (OHID)

Professor Marcus Munafò

Professor of Biological Psychology and MRC Investigator

School of Psychological Science, University of Bristol

Prof Thomas J. Glynn, PhD

Adjunct Lecturer

Stanford Prevention Research Center, Stanford University School of Medicine

Prof Wayne Hall

Professor Emeritus, National Centre for Youth Substance Use Research

The University of Queensland

Professor Robert West

Professor Emeritus of Health Psychology

University College London

Prof Martin Jarvis

Emeritus Professor of Health Psychology, Department of Behavioural Science & Health

University College London

Prof Robert Beaglehole

Emeritus Professor

University of Auckland, New Zealand & Chair ASH - Action for Smokefree 2025, NZ

Prof Caitlin Notley

Chair of Addiction Sciences

University of East Anglia

Prof Robin Mermelstein

Distinguished Professor of Psychology & Director, Institute for Health Research and Policy

University of Illinois, Chicago

Cliff Douglas JD

Director, Tobacco Research Network, Adjunct Professor, Dep't of Health Management and Policy

University of Michigan School of Public Health

Dr Jamie Hartmann-Boyce

Managing Editor, Cochrane Tobacco Addiction Group & Senior Research Fellow

University of Oxford

Dr Konstantinos Farsalinos M.D

External Research Associate

University of Patras, Department of Public and Community Health, University of West Attica, Greece

Prof Peter Hajek

Professor of Clinical Psychology

Wolfson Institute of Public Health, Queen Mary University of London